Loading...
KYMR logo

Kymera Therapeutics Community

NasdaqGM:KYMR Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

Community Investing Ideas

KYMR logo
Kymera Therapeutics

Advancing STAT6 And TYK2 Clinical Programs Will Open New Therapeutic Markets

Key Takeaways Advancing clinical programs and strategic partnerships could increase market share and positively impact future revenue and earnings. Solid cash runway supports focused R&D investments, potentially boosting long-term growth without immediate financing pressures.

View narrative
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
US$64.33
6.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-0.15% p.a.
Profit Margin
16.11%
Future PE
950.93x
Share price in 2028
US$77.83